Migraine firm enters clinic on back of million-dollar investment

Investors have come together to raise DKK 12m (USD 1.5m), enabling medtech company Rehaler to enter clinic. ”This will pave the way toward FDA approval,” says CEO Troels Johansen.

Rehaler's device to treat migraines goes by the company's name, and uses a person's own carbon dioxide to combat migraine attacks | Photo: Rehaler / PR

Medtech company Rehaler has received a capital injection of DKK 12m (USD 1.5m), which ensures one year of ongoing operations, CEO Troels Johansen tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs